TC BioPharm (TCB) is a biopharmaceutical business currently developing the closest to market drug candidate in Gamma Delta T (GDT) cell therapies.
TC BioPharm Limited
TC BioPharm (TCB) is a clinical development company with a cell-based product (CAR-T) pipeline capable of treating a variety of disorders including cancer and severe viral infections.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tc-biopharm-limited” connections=”true” suffix=””]
TCBs proprietary ImmuniCARë platform uses patients own of autologous ?? T immune cells grown in culture and supercharged using gene-therapy to target and kill specific cancer types, and has a safe history of use based on the treatment of numerous patients by Medinet in Japan.
In May 2018, TCB and Scotia Biologics signed a strategic collaboration to co-develop novel proprietary tumour-specific antibodies for TCBs CAR-T platform. Using Scotias unique, proven technology the two companies will develop a range of cancer-targeting single-chain antibodies, each of which can be formulated to treat a specific type of cancer. Antibodies developed by Scotia will be incorporated into TCBs therapeutic ImmuniCARë product range.
In Feb 2018, The NIPRO Corporation (TSE: 8086) and TCB, signed strategic collaboration to co-develop an autologous gamma-delta CAR-T therapy directed against CD19, which is expressed in several B cell tumors such as multiple myeloma and lymphoma. Preclinical studies developing the product will be supported by a Scottish Enterprise Çseek-and-solve grant which will provide £2.7m of additional non-dilutive funding. Further, The NIPRO Corporation will provide up-front fees, milestone payments and research-support to progress elements of TCBs CAR-T program to clinical studies and in turn holds an exclusive right to sell, and distribute CAR-T product worldwide.
In Dec 2017, bluebird bio, Inc. (Nasdaq: BLUE) and TCB signed license agreement to advance TC BioPharms lead CAR-engineered gamma delta T cell program into clinical trials as well as on additional hematologic and solid tumor targets. Under the terms, TCB is responsible for development of all targets through Ph 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis. TCB recieved $16 Mn upfront payment along with subsequent potential R&D and commercial milestone payments, with undisclosed royalties on product sales.
In Mar. 2014, TCB acquired an exclusively license to innovative cell therapy technology from MEDINET (Japan), for its clinical development in the UK and Europe.
In Aug 2017, TCB was awarded with 4 Mn grant funding under the European Unions Horizon 2020 (H2020) research and innovation programme to progress T cell therapy, and has raised over 25 Mn in funding since establishment.
In Mar. 2014, TCB secured initial funding of £1.3 Mn through grant support by Regional Selective Assistance (RSA) award and equity finance from MEDINET and Scottish investors. MEDINET presently holds 50% stake in TCB.